Abstract: Provided are compositions and methods for selectively reducing the amount of antibiotic resistant and/or virulent bacteria in a mixed bacteria population, or for reducing any other type of unwanted bacteria in a mixed bacteria population. The compositions and methods involve targeting bacteria that are differentiated from other members of the population by at least one unique clustered regularly interspaced short palindromic repeats (CRISPR) targeted DNA sequence. The compositions and methods can be readily adapted to target any bacteria or any bacteria plasmid, or both.
Abstract: A standardized, quantitative risk assessment method and apparatus for noninvasive melanoma screening. The apparatus and methods generate a melanoma Q-Score which calculates and displays a probability that a skin lesion is melanoma.
Abstract: The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.
Type:
Grant
Filed:
December 9, 2019
Date of Patent:
September 7, 2021
Assignee:
THE ROCKEFELLER UNIVERSITY
Inventors:
Vincent A. Fischetti, Jonathan Schmitz, Daniel Gilmer, Chad Euler
Abstract: 1-Phenylacetyl-8-aminohexahydro-2H-pyrano[3,4-b]pyrazines of formula are disclosed. The compounds are kappa ligands and are useful to treat drug dependency, pruritus, pain, and inflammation.
Type:
Grant
Filed:
December 7, 2018
Date of Patent:
August 17, 2021
Assignee:
The Rockefeller University
Inventors:
Mary Jeanne Kreek, Amy Ripka, Brian Reed, Eduardo Butelman
Abstract: 1-Phenylacetyl-8-aminohexahydro-2H-pyrano[3,4-b]pyrazines of formula are disclosed. The compounds are kappa ligands and are useful to treat drug dependency, pruritus, pain, and inflammation.
Type:
Application
Filed:
December 7, 2018
Publication date:
June 17, 2021
Applicant:
The Rockefeller University
Inventors:
Mary Jeanne KREEK, Amy RIPKA, Brian REED, Eduardo BUTELMAN
Abstract: 1-(3,4-Dihydro-1H-pyrido[4, 3-b]indol-2(5H)-yl)-2-hydroxyethanones are disclosed. The compounds are inhibitors of human cGAS in interferon-producing cell types. They are thus useful as therapeutic agents for treating cGAS-related autoimmune diseases in humans.
Type:
Application
Filed:
February 5, 2019
Publication date:
May 27, 2021
Applicants:
The Rockefeller University, Memorial Sloan-Kettering Cancer Center
Inventors:
Lodoe LAMA, Thomas TUSCHL, Daisuke TOMITA, Dinshaw PATEL, J. Fraser GLICKMAN, Taku KAMEI, Michael MILLER, Yasutomi ASANO, Rei OKAMOTO, Shogo HASHIZUME, Jumpei AIDA, Toshihiro IMAEDA, Mayako MICHINO, Takanobu KUROITA
Abstract: The present disclosure relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant S. aureus (MRSA) and vancomycin intermediate S. aureus (VISA).
Type:
Grant
Filed:
August 20, 2018
Date of Patent:
May 25, 2021
Assignee:
The Rockefeller University
Inventors:
Vincent A. Fischetti, Anu Daniel, Chad Euler
Abstract: The disclosure provides methods for isolating nucleic acids from a biological fluid. In one aspect, the disclosure provides a method for isolating RNA. In another aspect, the disclosure provides a method for isolating DNA. In one aspect, the methods described herein utilize a protocol that combines a detergent-based initial denaturation, protease digestion, and organic extraction followed by column purification that maximizes RNA/DNA yield and preserves RNA/DNA integrity. In yet another aspect, the disclosure provides a kit for isolating RNA and/or DNA.
Type:
Grant
Filed:
December 31, 2015
Date of Patent:
April 6, 2021
Assignee:
THE ROCKEFELLER UNIVERSITY
Inventors:
Klaas Max, Karl Bertram, Kemal Akat, Thomas H. Tuschl, Jenny Li, Kimberly Bogardus
Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
Abstract: Methods and compositions are provided for translational profiling and molecular phenotyping of specific tissues, cells and cell subtypes of interest. The methods provided herein facilitate the analysis of gene expression in the selected subset present within a heterogeneous sample.
Type:
Grant
Filed:
September 29, 2017
Date of Patent:
March 16, 2021
Assignee:
The Rockefeller University
Inventors:
Nathanial Heintz, Paul Greengard, Myriam Heiman, Anne Schaefer, Joseph P. Doyle, Joseph D. Dougherty
Abstract: Processes to identify variants that affect biochemical regulation are described. Generally, models are used to identify variants that affect biochemical regulation, which can be used in several downstream applications. A pathogenicity of identified variants is also determined in some instances, which can also be used in several. Various methods further develop research tools, perform diagnostics, and treat individuals based on identified variants.
Type:
Application
Filed:
January 28, 2019
Publication date:
March 11, 2021
Applicants:
The Trustees of Princeton University, The Simons Foundation, Inc., The Rockefeller University
Inventors:
Jian Zhou, Christopher Y. Park, Chandra Theesfeld, Robert B. Darnell, Olga G. Troyanskaya
Abstract: The present invention generally relates to compositions and methods for inhibiting host-seeking behavior, blood-feeding, and biting in blood-feeding arthropods. The present invention also generally relates to compositions and methods for inhibiting the attraction of blood-feeding arthropods to a host. More particularly, the present invention relates to compositions and methods for inhibiting the host-seeking behavior and biting of mosquitos and inhibiting their attraction to humans.
Abstract: An imaging signal extraction apparatus comprising: an interface; a processing device, the processing device operatively coupled to the interface; and a computer readable medium comprising instructions that, when executed by the processing device, perform operations comprising: a) generating a two-dimensional image from imaging information obtained from the interface, thereby estimating ballistic component of the imaging information; b) generating a three-dimensional image by remapping the two-dimensional image; c) identifying a candidate object in the three-dimensional image; d) obtaining an estimated spatial forward model of the candidate object by mapping the three-dimensional image of the candidate object with a point-spread-function associated with the imaging apparatus; e) obtaining background-corrected data by using the estimated spatial forward model of the candidate object and estimated temporal components; and f) iteratively updating the estimated spatial forward model and estimated temporal componen
Type:
Application
Filed:
October 7, 2020
Publication date:
February 4, 2021
Applicant:
The Rockefeller University
Inventors:
Alipasha Vaziri, Tobias NOEBAUER, Oliver SKOCEK
Abstract: This invention concerns pathological angiogenesis and cancer, related treatment methods, and related compositions. Also disclosed are related diagnosis kits and methods.
Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
Type:
Grant
Filed:
September 29, 2017
Date of Patent:
January 12, 2021
Assignees:
The Rockefeller University, California Institute of Technoloqy
Inventors:
Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
Abstract: The present invention relates to anti-tumor agents that target certain tumor-associated macrophages. Also disclosed are methods of using such agents in treatment of cancer.